Resumo

MARTINEZ, Carolina et al. Uso de taxanos en neoadyuvancia en cáncer de mama resistente a antraciclinas. Rev. venez. oncol. [online]. 2006, vol.18, n.3, pp.144-151. ISSN 0798-0582.

OBJECTIVES: The addition of anthracyclines in the neoadjuvant chemotherapy has increased the rates of clinical response, which, it has increased with the introduction of the taxanes, mainly as far as pathological answer one talks about. The primary objective of this work was to determine the effectiveness of the taxanes in neoadyuvance in patients with locally advanced breast cancer, that initially they failed to regimes based on antraciclines. METHODS: We evaluated 19 patients who had received contentious regimes of anthracyclines (Cyclophosphamide - adriamicine or fluoracil - adriamicine - cyclophosphamide), being made clinical evaluation of tumoral size and, by means of the ultrasound and directed biopsies, for tumoral necrosis percentage. Them, they were enlisted to receive taxanes (Paclitaxel or docetaxel) by 4 cycles and finally were under surgical treatment. RESULTS: A rate of objective clinical answer of 73.68 % was observed (14 patients), including complete answer in 31.57 % (6 patients) and partial answer in 42.1 % (8 patients). Five patients remained with stable disease (26.31 %) and one patient presented progression of disease, going to third line treatment (5.26 %). Also, the rate of pathological answer in the 18 surgical patients was evaluated, with a rate of total pathological answer of 22.2 %. CONCLUSIONS: The taxanes given in sequential form after induction chemotherapy in patients with refractory anthracyclines chemotherapy based to operable breast cancer were in an increase in the clinical and pathological answer, which strongly supports the results published in literature.

Palavras-chave : Cancer; breast; treatment; chemotherapy; adyuvant chemotherapy; antraciclines resistance; taxanes.